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Summary Photodynamic therapy is a potential treatment for superficial bladder cancer that utilizes photosensitizer drugs, which are
activated by light to cause tissue destruction. However, first-generation photosensitizers cause prolonged phototoxicity, have poor tumour
specificity and can accumulate within detrusor muscle, resulting in permanent loss of bladder capacity following treatment. A newer drug,
called 5-aminolaevulinic acid (ALA), generates a sensitizer called protoporphyrin IX (PpIX) in situ and has been shown, qualitatively, to be
more tumour specific. The fluorescence kinetics of ALA-induced PpIX was investigated in patient biopsies of bladder tumour, normal
urothelium and detrusor muscle, both in vitro after incubation of specimens in ALA-rich culture medium for various times and in vivo after
instillation of intravesical ALA before endoscopic resection. The fluorescence in tumourtissue was twice that of normal urothelium in vitro and
up to tenfold in vivo. There was little ALA-induced fluorescence in detrusor muscle, both in vitro and in vivo. Most importantly, no patients
experienced phototoxicity or other adverse events following intravesical instillation of ALA.
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Photodvnamic therapx (PDT) is a method for the treatment of
cancer based on the svstemic or topical administration of drugrs
called photosensitizers. which are activated in the presence oflight
to cause cell death and tissue destruction. Ideally. photosensitizers
should be selectively retained by tumour. leaving adjacent tissue
undamaged following, light activation. although in practice this has
been difficult to attain (Bown. 1989).
Transitional cell carcinomas (TCCs) of the bladder are ideal for
this type of treatment because. with careful control of the lirht
distribution. curative doses can reach all parts of the urothelial
surface (D'Hallewin et al. 1992). This is of importance in prob-
lematic superficial tumours. which are often multifocal. Areas of
poorly defined dysplasia and carcinoma in situ are therefore
amenable to effective photodynamic therapy.
First-generation sensitizers. such as haematoporphyrin deriva-
tive. are usually administered systemically. This results in the
inevitable distribution of drug to various organs such as the skin.
with skin photosensitivity often exceeding 6 weeks (Doughertv et
al. 1990). The most significant morbidity from photodynamic
treatment of the bladder arises. however. from the relatixve lack of
selectivity ofhaematoporphynn-based sensitizers between mucosa
and detrusor muscle. Furthermore. intravesical administration is
unreliable with these photosensitizers. and this also means that the
transitional cell layercannot act as a natural barrier to the uptake of
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these sensitizers (Benson. 1988). Partly as a result ofthis. photody-
namic therapy of the bladder using first-generation sensitizers has
been associated with serious damage to. and therefore functional
impairment of. the detrusor muscle (Nseyo et al. 1985).
The use of an endogenous substance. 5-aminolaev-ulinic acid
(ALA). to generate the synthesis in situ of the pure porphyrin.
protoporphyrin IX (PpLX) with minimal toxicity. represents a new
strategy in the administration of photosensitizing drugs. ALA. a
natural precursor of haem. is a low-molecular weight substance
which is taken up by all nucleated cells. The immediate precursor
of haem is PpIX and. because this final step is rate-limiting.
exogenous ALA results in the accumulation of PpIX. which is an
effective photosensitizer which can be exploited for photodynamic
therapy. Intravenous administration of ALA results in rapid clear-
ance from the body. with no detectable PpIX fluorescence in the
skin or other organs after 24 h (Kennedy et al. 1991 ). It has been
previously demonstrated (Steinbach et al. 1994). using qualitative
measures. that intravesical ALA in human subjects can induce
selective porphyrin accumulation within bladder tumour.
compared with normal urothelium and detrusor muscle. Studies of
intravesical ALA in the rat bladder confirm that selective accumu-
lation of sensitizer was 11 times greater than in detrusor muscle
(Chang et al. 1996a). The importance of mucosal selectivity was
demonstrated by showing that subsequent photodynamic damage
to the bladder wall was minimal (Chang et al. 1996b).
The purpose of this study was therefore to determine. quantita-
tiv-ely. the fluorescence kinetics of ALA-induced PplX in human
TCC. compared with normal urothelium and detrusor muscle in
vitro. A further objective was to establish the kinetics of endooe-
nous porphyrin induced by intravesical ALA in selected patients.
with a particular emphasis on recording adverse events.
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PATIENTS, MATERIALS AND METHODS
Before the instillation of intraxesical ALA into patients. an in vitro
study of the kinetics of ALA-induced porphyrin fluorescence xxas
performed on tissue samples taken from patients. This w as carried
out to determine the approximate time for ALA-mediated PpIX
fluorescence to reach a maximum and to determine the abilitv of
different tissue samples to synthesize porphyrin photosensitizer.
In vitro study of ALA-mediated fluorescence kinetics
Patients
All studies involving patients had received local research ethics
committee approval. Informed consent wxas obtained from all
patients. Specimens for determining the fluorescence kinetics of
ALA uptake were obtained from sexen patients with a prexious
histor- of superficial transitional cell carcinoma of the bladder.
Patients were admitted for endoscopic resection of their tumours
after a recent diagnosis on flexible cystoscopx oftumour recurrence.
Collection ofbiopsy specimens
Before conxentional endoscopic resection. two or three cold-cup
biopsies were taken from tumour. normal urothelium and detrusor
muscle. These were dixided with a sterile scalpel such that there
were four or fixe specimens of tumour. normal urothelium and
detrusor muscle from each patient. The specimens were immedi-
ately transported to the laboratory in warm. sterile Hartmann's
solution.
Incubation ofspecimens in ALA-rich culture medium
Biopsy specimens were incubated in RPMI tissue culture medium
(Imperial). supplemented with 10% fetal calf serum (FCS: Gibco
BRL). 50 U ml penicillin/ 50 jgc ml-' streptomycin (Gibco BRL).
2 m-M L-glutarnine (Gibco BRL) and 1 nmL ALA (Signa) buffered
to a pH of 7. In patients from whom five biopsy samples were
available from each ofthe three tissue types. the fifth tissue sample
was immediately snap frozen and used to determine tissue back-
ground fluorescence. The other four specimens were incubated
for 2. 4. 6 or 24 h at 37 C in an atmosphere of 95% oxygen and
5%e carbon dioxide. Light exposure was minimiized to avoid
bleachinc of photosensitizer. After incubation. biopsy material
was embedded (Tissue Tek II embeddinc compound. BDH) and
snap frozen in a bath of isopentane prechilled in liquid nitrogen.
Paired frozen sections 10 jm thick wxere cut from each tissue
block using a cryotome. One section from each pair was fixed and
stained with haematoxylin and eosin. The other paired frozen
section was left unstained and stored at -70 C until fluorescence
microscopy and photometrvxwere carried out. All specimens were
stored at -70cC until frozen sections were prepared and fluores-
cence microscopy and photometrv carried out. as described later.
In vivo clinical study of ALA-mediated fluorescence
kinetics
Patients
Local research ethics committee approval was obtained.
Permission was obtained from the UK Department of Health for
instilling intraxesical ALA. under the prox isions of the Medicines
(exemption from licences) (special cases and miscellaneous provi-
sions) Order. 1972. Informed consent wxas obtained from ten
patients with a previous known history of superficial transitional
Table 1 Details of patient's age. tissue fluorescence. duration of ALA
instillation. tumour stage and grade. and adverse events
Patient Age Instillation Histology Adverse
no. time (h) events
1 68 3.5 TaG2 None
2 49 2 TaG1 None
3 76 2.5 TaG2 None
4 57 3 TaG1 None
5 73 2.5 TaG1 None
6 66 1.5 TaG2 None
7 57 3 TaG1 None
8 68 1 .25 TaG1 None
9 63 4.5 Dysplasia None
10 75 2.5 Chronic inflammation None
cell carcinoma of the bladder. AWritten details concerning ALA
instillation and fluorescence cystoscopy were given to each
patient. All patients had recentl1 had recurrences diagnosed or
suspected from flexible cystoscopy. Patients A-ith a history of
pel-ic radiotherapy. invasix e bladder cancer or a bladder symptom
score (IPSS) greater than 7 A-ere excluded. Before the instillation
of intravesical ALA. blood samples. anticoagulated in EDTA.
were taken for full blood count and baseline plasma porphyrin
lexels and serum samples for urea and electrolyrtes and liver func-
tion tests. Total plasma porphvrins Aere determined spectrofluoro-
metrically. In six patients. uroflowx parameters w-ere measured
before instillation using a urine flowx meter. and the post-micturi-
tional residual estimated using an ultrasound scanner (Bard
Bladderscan).
Instillation ofintravesical ALA
Between 2 and 5 h preoperatively. 50 ml of 3%le ALA (Sigma) was
instilled intravesical1v Xia a 12-F Lofric catheter. The solution w-as
prepared by dissolvinc 1.5g of ALA in 50 ml of physiological
saline buffered to a pH of 6.5 with 8.4%- sodium bicarbonate. The
solution Aas freshly prepared and sterilized by ultrafiltration at the
Department of Pharmacy of the University Hospital. Cardiff. UK.
Solutions of ALA were instilled w-ithin 3 h of preparation and
refrigerated in the dark- until used.
Fluorescence cystoscopy
Under spinal or general anaesthesia. all instilled ALA was drained
and subsequent cystoscopy carried out using sterile 1.5%e glNcine.
Conventional cystoscopy A-ith w-hite light w-as briefly carried out.
followed by fluorescence cystoscopy. This has previously been
descnrbed to determine qualitatively the preferential nature of
ALA fluorescence kinetics within tumour and for possible early
detection of bladder cancer (Kriegmair et al. 1994. 1996a).
Fluorescence cystoscopy is based on the principle that ALA
induces the preferential generation of the endogenous fluorescent
porphyrin PpIX within tumour. Usinc a 300-W D-light xenon arc
lamp x-ith a bandpass filter (375-440 nm) (Karl Storz). PpIX fluo-
rescence A-as induced using violet light. Red fluorescence w-as
detected using a longpass filter integrally attached to the cvsto-
scope. A foot pedal A-as used to switch betwxeen xiolet light for
fluorescence and white light for conxentional cystoscopy. Both
fluorescence and conventional cystoscopyxA-ere carried out brieflv
to avoid excessive photobleaching of sensitizer.
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Figure 1 Fluorescence kinetics of patient bladder biopsies incubated in
vitro in ALA-nch culture medium. Fluorescence is measured in arbitrary units.
Values take into account background autofluorescerce determined from
control specimens. Error bars represent the standard error of the mean
(s.e.m.). *. Tumour S. normal urothelium. A. muscle
Collection ofbiopsy specimens
Using conventional cystoscopy. cold-cup biopsies Were tak-en from
each of tumour or abnormal urothelium. normal urothelium and
detrusor muscle. These specimens A-ere immediately transported
to the laboraton-. where tissue blocks were embedded (Tissue Tek
II embedding compound. BDH) and snap frozen in a bath of
isopentane prechilled in liquid nitrogen. Paired frozen sections
10 gm thick wxere cut from each tissue block using a cryotome.
One section from each pair A-as fixed and stained w-ith haema-
toxvlin and eosin. The other paired frozen section was left
unstained and stored at -70-C until fluorescence microscopy and
photometrx were carried out.
Post-operative care
Approximately 1-5 h after instillation of ALA. a blood sample for
plasma porphy-rin determination w-as collected from each patient.
via a 14-G enous cannula inserted perioperatively. Approximately
24 h after instillation. further samples were taken from the venous
cannula for full blood count. creatinine. electrolyrtes. liver function
tests and further plasma porphyrin levels. Patients were usually
discharged on the second post-operative day. Patients w-ere advised
prospectively of possible phototoxicity and asked to record all
adverse exents. Patients were reviewed in the outpatient clinic
within 2-3 w-eeks and adverse events noted. Further blood samples
wxere taken for full blood count. creatinine. electrolytes and liver
function tests. Urofloxx parameters were recorded in those patients
with preoperative flow- rate and post-micturition residual measure-
ments. Bladder symptom scores (IPSS were recorded in all
patients at this stace.
Fluorescence microscopy andphotometry
Unstained frozen section slides wxere transported to the laboratory
in drn ice and only allowed to thaxx before fluorescence
microscopy. Fluorescence microscopy was performed as described
prexiouslI (Bedwxell et al. 1992: Loh et al. 1992l. An inverted
microscope (Oix mpus IM-2) with epifluorescence and phase-
contrast attachments vvas used. A 10 x objectixe w-as used to giVe
images of 880 x 550 gm dimensions. Fluorescence A-as excited
using an 8-mW helium neon laser operating at 632.8 nm. with the
output directed onto a dichroic mirror in the epifluorecence micro-
scope through a liquid light guide and xia a 10-nm bandpass
filter to remove extraneous light. The advantage of using the
helium-neon laser for excitation is its spectral puritx and the
induction ofless tissue autofluorescence. Exposure time w-as set at
25 s. using an excitation fluence of <1 J cm-'. Fluorescence w-as
detected in the range 660-710 nm using a combination of band-
pass (Omeca Optical) and longpass (Schott RG655) filters. Under
these conditions. porphyrin photodegradation was negligyible. The
fluorescence sianal was detected by a highlx sensitixe crvogeni-
callv cooled slow--scan charge-coupled dexice (CCD) camera of
resolution 400 x 600 pixels (Wright Instruments) attached to the
microscope. The signal w-as processed via an IBM personal
computer into a colour-coded digital image of the section
depicting mean signal counts per pixel. Fluorescence in terms of
counts per pixel (four photoelectrons per count: quantum effi-
ciencv0.5 at this A-avelength wAas quantified digitally oxer at least
three equal areas ofinterest for each section. Areas ofinterest w-ere
chosen to be representatix e of the entire histological section.
avoiding cold biops- crush artefacts. Both unstained and stained
pairs of tissue sections were checked histologicallx using light
microscopy. Autofluorescence of control specimens of bladder
tumour. normal urothelium and detrusor muscle. which A-ere not
exposed to ALA. A-as measured and this data was subtracted from
the relatixe fluorescence -alues of corresponding ALA-exposed
tissue.
RESULTS
Results of in vitro fluorescence kinetics of ALA-
mediated accumulation of PpIX
Incubation of tissue samples in ALA resulted in an initial time-
dependent increase in tissue fluorescence for all three tissue types
over the first 2-6 h. Howexer. the increase in detrusor muscle
tissue fluorescence w-as relatively small compared w-ith that of
tumour and normal urothelial tissue. The peak- fluorescence in
tumour tissue was double that ofnormal urothelium and nearly six
times that of detrusor muscle. Tumour fluorescence appeared to
peak between 2 and 6 h of incubation in ALA. but. by 24 h. this
had diminished to fluorescence levels similar to those of normal
urothelium and detrusor muscle (Ficure 1).
Results of in vivo study
Results offluorescence cystoscopy
Of ten patients in whom intravesical ALA A-as administered. eight
had evaluable superficial bladder tumours. Cystoscopx of these
patients using the violet excitation light source resulted in bright
red fluorescence ofall tumours identified using conventional Ahite
light. In one patient. conventional cystoscopy revealed a flat. red
area of bladder which did not fluoresce when the light source was
switched. This area A-as biopsied and subsequent histological
examination confirmed features consistent with chronic inflamma-
tion. In a second patient with a previous history of carcinoma in
situ. however. w-hite light cystoscopy A-as unremark-able although
an area near the trigone fluoresced brightly. This area was biopsied















































Photodvnamic therapy of bladder cancer was first described in
1976. although results were limited because of the lack of reliable
light dosimetry (Kellv and Snell. 1976). The spheroid shape of the
bladder also enables reasonably uniform light delivers and the
abilitv for the whole urothelial surface to be treated simultane-
ouslv (Pope and Bow-n. 1991). This is of importance in resistant
superficial tumours that are often multifocal. Areas of poorly
defined dysplasia and carcinoma in situ do not. therefore. neces-
sarilv need to be precisely defined for effective photodynamic
therapy to take place. The results described in this paper are
complementary to the pioneering work of Kriegmair and
5 6 7 8 colleagues (Kriegmair et al. 1994. 1996a: Steinbach et al. 1994)
Patient who demonstrated. qualitatively. that ALA can be delix ered
intravesicallv with the resultant preferential accumulation of
photosensitizer within tumour. The w-ork described in this paper
Fluorescence of bladder biopsy specimens removed from patients complements Kriegmair's bv recording. quantitativelv. the
luentty confirmed tumour. Fluorescence is measured in arbitrary . -
bs take into account background autofluorescence determined relative accumulation of PpIX in tumour compared w-ith normal
A specimens. S. Tumour., * normal: A, muscle urothelium and detrusor muscle. The method we used to measure
PpIX accumulation within the X arious tissues has been well
described and A-as carried out using, fluorescence microscopy.
utilizing a highly sensitive CCD camera (Bedwell et al. 1992:
Regula et al. 1995). Loh et al (1993) were able to show. using
high-performance liquid chromatography (HPLC). that the ALA-
todiathermied. Histological examination confirmed induced fluorescence measured using CCD technology is
although this did not amount to frank carcinoma in situ. porphyrin mediated and that PpIX constitutes >95%7 of the fluores-
cence measured in this way. Importantly. the degree of PpIX-
ence kinetics ofintravesical ALA mediated fluorescence that we measured in the various bladder
tients with evaluable bladder tumours. the amount of tumour specimens is similar to previously described lexels of
issue fluorescence after intravesical ALA was at least tissue fluorescence. which correspond to levels of PpIX that can
id. in some cases. up to ten times that of normal urothe- mediate photodynamic damage in vivo (Bedwell et al. 1992: Fan
fluorescence in detrusor muscle was often barely above et al. 1996).
)round autofluorescence of control tissue (Figure 2). In In contrast. the in vitro kinetics of ALA-induced fluorescence
(patient 6). there was no difference in fluorescence from described in this paper suggest that detrusor muscle has an
nd normal urothelium. In this patient. the tumour was intrinsic inability to accumulate significant levels of photosensi-
pically pedunculated with extensive papillary folding. tizer. The efficacy of intravesical ALA will probably enhance this
of tumour architecture will probably reduce the available factor because of the natural bamrer of the urothelial layer in
-ea for topical sensitization and could explain the reduced protecting the underlying muscle wall. Furthermore. the in vitro
nce of tumour in this patient. studies were carried out by incubating biopsy specimens in
medium containing serum. This is likely to reduce the measured
sffect ofintravesical ALA fluorescence within the specimens. because ALA-induced PpIX is
llation of intravesical ALA was well tolerated in all lipophilic and is sequestered from cells owing to binding with
Apart from the minor discomfort associated with the serum proteins. Conversely. when ALA is administered intravesi-
of a 12-F Lofric catheter under local anaesthesia. intra- cally. the generated PpIX is less likely to diffuse into the ALA
stillation was in itselfcompletely painless. There were no aqueous solution and urine. This could also explain. at least in
sof persistent dysuria or frequency following post- part. the enhanced degree of ALA-induced fluorescence seen after
catheter removal. Baseline plasma porphyrin levels were intravesical administration compared with the in vitro studies. Our
normal range in all patients (< 10 nmol 1-). and a rise in study prospectively monitored adverse events and clearly shows
not occur in either the 2-4 h sample or the 24-h sample. that phototoxicity did not occur in any of our cohort of patients.
ochemical and haematological parameters remained The absence of any rise in plasma porphyrins after intravesical
normal range both pre- and post-operatively. Before ALA suggests that systemic absorption is minimal and that the risk
ative discharge. patients were asked prospectively to of phototoxicity is negligible.
Iverse events. In particular. patients were warned about Between 1983 and 1995. at least 15 published series of patients
)hototoxicity. but no particular advice was given to avoid receiv-ing photodvnamic therapy using haematoporphyrin derin
a-
ylight. However, no phototoxic or other adverse events tive
or Photofrin for bladder cancer have been published (Pope
nrted in any of the patients. The bladder symptom scores and Bown. 1991). Most of these studies utilized highlyv variable
ents were similar at 2-3 weeks afterdischarge. compared selection criteria. with different tumour types and using, different
peratively. Uroflowmetrv and post-micturition residuals photosensitizer and light doses. How-ever. the average complete
ittle changye in those patients in whom these parameters response rate of photodynamic therapy reported in these is
sured. Patient details are summarized in Table 1. approximately 68% at 3 months. The best responses are achieved
British Joumal of Cancer (1998) 78(8), 1113-1118
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in patients with carcinoma in situ (D'Hallewin and Marijnissen.
1995). with 100% initial complete response rates reported. The
overall success of photodynamic therapy of the bladder using
haematoporphyrin derivative and Photofrin is. therefore. of a
similar order ofmagnitude to intra-esical chemotherap-. w-ith ver-
encouraging results for carcinoma in situ. although no comparative
studies exist in this respect. Furthermore. there are no long-term
studies looking at lon2-term disease progression or survival.
Despite the encouraging results of limited early clinical studies.
haematoporphyrin deri ative and Photofrin-mediated photo-
dynamic therapy ofbladder have remained experimental treatment
modalities within the field ofuro-oncologv. Much of this has been
due to adverse events which. while usually not danaerous. often
result in symptoms which have a profound effect on the quality of
life. The use of an endogenous substance. 5-aminolaevulinic acid
(ALA). to generate the synthesis in situ of the pure porphyrin.
protoporphyrin IX (PpIX). therefore represents a new- strategy.
Intravenous administration ofALA results in rapid clearance from
the body uwith no detectable PpIX fluorescence in the skin or other
organs after 24 h (Kennedy and Pottier. 1992).
Despite the promising nature of the role of ALA-mediated
photodynamic therapy of bladder tumours. little work has as vet
been reported in this field. One group was able to induce necrosis
of the urothelial layer of rat bladder using 50 J of laser light. but
with minimal detrusor damage (Chang et al. 1996b). The opportu-
nity of administering ALA intravesically not onlv allows the
urothelium to act as a potential barrier to sensitizer accumulation
within detrusor. but also theoreticallv reduces the risk of skin
photosensitivity. assuming that there is minimal absorption of
ALA by the transitional cell laver. It has been demonstrated quali-
tativelv that intravesical ALA in human subjects induces photo-
sensitizer uptake within normal and neoplastic urothelium. with
minimal detrusor accumulation (Steinbach et al. 1994). Using a
krypton laser to induce fluorescence rather than tumour destruc-
tion. the same group has exploited the preferential accumulation of
sensitizer within tumour as a diagnostic tool to enhance cysto-
scopic visualization of poorly defined dysplasias and carcinomas
in situ (Kriegmair et al. 1994. 1996a). However. these studies were
confined to establishina the qualitative differences between ALA-
induced fluorescence in tumour and non-tumour tissue. W'e have
been able to reproduce the technique of fluorescence cystoscopy.
and also determine. quantitatively. that ALA-mediated fluores-
cence is up to 11 times greater in transitional cell tumourcompared
with normal urothelium. The fluorescence intensity- within the
Various tumour specimens is summarized in Table 1. There does
not appear to be a clear difference between patients with moder-
atelv differentiated or well-differentiated tumours.
To date. there is only one report ofALA-mediated photodynamic
therapy ofbladder cancer in patients (Kriegmair et al. 1996b). This
study is an early report ofthe treatment of ten patients with bladder
cancer refractor- to other treatment modalities. Different light
doses and laser wavelengths were used in different patients after the
instillation of 10`%1 ALA. but complete or partial responses were
reported in six of these subjects. The ability of intravesical ALA
to induce the preferential accumulation of photosensitizer within
tumour tissue. with minimal adverse e-ents. is an important consid-
eration in further development ofphotodynamic therapy of superfi-
cial bladder cancers. Superficial bladder cancers have long been
shown to be a suitable target for photodynamic treatment. Early
carcinoma in situ is a clear example of a potentially dangerous
bladder cancer. with si5nificant recurrence rates despite intravesical
chemotherapy. Often. radical cystectomy is the only solution for
this scenario. but. with close to 100'% response rates. photodynamic
therapy is clearly a promising solution for this particular problem.
However. serious adverse events associated with first-generation
sensitizers has meant that this treatment modality has remained
experimental within the urological community. Intravesical ALA
appears to generate the preferential accumulation ofphotosensitizer
w-ithin bladder tumour with minimal toxicitv. thus offerin2 the
prospect of photodvnamic therapy occupying a potentially impor-
tant niche in the urologist's armamentarium.
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